Aromatase inhibitors ‘eclipse tamoxifen’ in younger women
Among patients with early breast cancer undergoing ovarian suppression, aromatase inhibitors cut tumour recurrence by a third, data show
Replacing tamoxifen with an aromatase inhibitor in premenopausal women receiving ovarian suppression therapy significantly decreases the risk of breast cancer recurrence, a meta-analysis shows.
However, use of the agents — including anastrozole, exemestane or letrozole — appeared to have no impact on breast cancer mortality, an international research collaboration has found.
